StockNews.AI
A
StockNews.AI
148 days

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

1. Agilent supports Autolus's FDA approval for CAR T therapy AUCATZYL. 2. xCELLigence technology was critical in potency assay validation.

FDA Approval
-0.14%Current Return
VS
+1.79%S&P 500
$120.7503/24 08:09 AM EDTEvent Start
$120.5803/25 02:46 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The involvement in FDA approval can positively boost Agilent's reputation and sales, similar to past occurrences with successful biotech collaborations.

How important is it?

The article highlights a significant milestone in Agilent's business strategy and market positioning in the biotechnology sector, directly influencing its long-term growth potential.

Why Long Term?

Partnerships in successful drug approvals often lead to extended revenue streams, impacting financial performance positively over years.

Related Companies

AUTL
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a.

Related News